Previous 10 | Next 10 |
Vaccinex (NASDAQ: VCNX ): Q3 GAAP EPS of -$0.56 beats by $0.10 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Mee...
ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepine...
GERMANTOWN, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Gl...
Updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating the combination of Vaccinex's (NASDAQ: VCNX ) lead candidate pepinemab and Pfizer (NYSE: PFE ) and Merck KGaA's ( OTCPK:MKGAF ) Bavencio (avelumab) in patients with treatment-resistant advanced non-small cel...
ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepin...
ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive ...
Vaccinex (NASDAQ: VCNX ): Q2 GAAP EPS of -$0.77. More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical Oncology (ASCO) Annu...
Vaccinex ( VCNX -1.5% ) announces full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer's ( PFE +0.6% ) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC). Mor...
News, Short Squeeze, Breakout and More Instantly...
2024-04-17 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clin...